Pharmaceutical Excipient Market by Type (Inorganic, Organic), Formulation (Oral Formulations, Parenteral Formulations, Topical Formulations), Function, End-User - Global Forecast 2025-2030
ÀǾàǰ ÷°¡Á¦ ½ÃÀåÀº 2023³â¿¡ 86¾ï 2,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 92¾ï 2,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 7.62%·Î ¼ºÀåÇϰí, 2030³â¿¡´Â 144¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀǾàǰ ÷°¡Á¦´Â ÀǾàǰÀÇ À¯È¿¼ººÐ(API)°ú ÇÔ²² ¹èÇյǴ ºÒȰ¼º ¹°Áú·Î ÀǾàǰÀÇ ¾ÈÁ¤¼º, »ýüÀÌ¿ë·ü, Àü´ÞÀ» ÃËÁøÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ´Ù¾çÇÑ ÀǾàǰ Á¶Á¦¿¡ ÇʼöÀûÀ̸ç, °áÇÕ, ÄÚÆÃ, °¡´É ¿ëÈ, º¸Á¸ µîÀÇ ±â´É¼ºÀ» Á¦°øÇÕ´Ï´Ù. ÷°¡Á¦´Â °æ±¸Á¦, ¿Ü¿ëÁ¦, ºñ°æ±¸Á¦, ÈíÀÔÁ¦ µî ´Ù¾çÇÑ ¿ëµµ·Î ÀÌ¿ëµÇ°í ÀÖÀ¸¸ç, ÁÖ¿ä ÃÖÁ¾ ¿ëµµ ºÐ¾ß´Â º´¿ø, Áø·á¼Ò, ¿¬±¸ ±â°ü µîÀÔ´Ï´Ù ÀǾàǰ ÷°¡Á¦ ½ÃÀåÀÇ ¼ºÀåÀº ÁÖ·Î Á¦¾à ºÎ¹®ÀÇ È®´ë, ÀǾàǰ Çã°¡ Áõ°¡, ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ »ó´çÇÑ Áøº¸¿¡ ÀÇÇØ ÃÊ·¡µË´Ï´Ù. ¾ö°ÝÇÑ ±ÔÁ¦ Áöħ ¹× ½Å±Ô ÷°¡Á¦ÀÇ °³Ã´¿¡ ¼ö¹ÝÇÏ´Â °íºñ¿ë°ú °°Àº °úÁ¦¿¡ Á÷¸éÇϰí ÀÖ¾î À̰ÍÀÌ ¼ºÀåÀÇ ¹æÇذ¡ µÉ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ÷°¡Á¦ Ư¼ºÀÇ ÆíÂ÷¿Í °°Àº ÇѰ赵 ÀÖ½À´Ï´Ù.
ÁÖ¿ä ½ÃÀå Åë°è |
±âÁسâ(2023) |
86¾ï 2,000¸¸ ´Þ·¯ |
ÃßÁ¤³â(2024) |
92¾ï 2,000¸¸ ´Þ·¯ |
¿¹Ãø³â(2030) |
144¾ï 2,000¸¸ ´Þ·¯ |
CAGR(%) |
7.62% |
ÃֽŠºñÁî´Ï½º ±âȸ·Î´Â ¹ÙÀÌ¿À ÀǾàǰ¿¡ ´ëÇÑ ÁÖ¸ñÀÇ Çâ»ó°ú ¸ÂÃãÇü ÀÇ·áÀÇ µµÀÔ È®´ë°¡ ÀÖ½À´Ï´Ù. ÆéƼµå ¹× ´Ü¹éÁú Á¦ÇüÀÇ Ã·°¡Á¦ °³¹ß¿¡¼ »ý¸í °øÇÐ ±â¾÷°úÀÇ Çù·Â °ü°è¸¦ ¸ð»öÇÏ¸é ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÉÁö¾î °æÀï ¿ìÀ§¸¦ °¡Á®´Ù ÁÙ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ½ÃÀåÀº ¸Å¿ì ¿ªµ¿ÀûÀÌ¸ç ±Þ¼ÓÇÑ ±â¼ú Áøº¸¿Í Â÷¼¼´ë ÷°¡Á¦ÀÇ °·ÂÇÑ ÆÄÀÌÇÁ¶óÀÎÀÌ Æ¯Â¡ÀÔ´Ï´Ù. ¿¬±¸ °³¹ß ÅõÀÚ¿¡ ÁÖ·ÂÇÏ°í °øµ¿ ¿¬±¸¸¦ Ȱ¿ëÇÏ¿© ´É·ÂÀ» ³ôÀ̰í ÃֽŠÀǾàǰ Á¦Á¦ÀÇ ´Ù¾çÇÑ ¼ö¿ä¿¡ ºÎÀÀÇØ¾ßÇÕ´Ï´Ù.
½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈÇÏ´Â ÀǾàǰ ÷°¡Á¦ ½ÃÀå¿¡¼ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® ÇØ¸í
ÀǾàǰ ÷°¡Á¦ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ¾ò´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ÀÌ´Â Á¦Á¶ ºñ¿ë°ú ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ´õ¿í ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ¼¼°èÀÇ ¾Ï ¹× ±âŸ ¸¸¼º¡¤°¨¿°Áõ ÀÌȯÀ²ÀÇ »ó½Â
- Á¦³×¸¯ ÀǾàǰÀ̳ª Èñ±ÍÀǾàǰ¿¡ ´ëÇÑ Å« ¼ö¿ä¿Í ÇÔ²² ÀǾàǰ ¾÷°èÀÇ ¼ºÀå
- ´Ù±â´É ÷°¡Á¦ÀÇ Á¦Á¶ÀÇ Áß½Ã
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- °íµµÀÇ Ã·°¡Á¦ÀÇ Á¦Á¶¿¡ ¼ö¹ÝÇÏ´Â °íºñ¿ë
- ½ÃÀå ±âȸ
- ÷°¡Á¦ÀÇ ³ª³ë±â¼ú ±â¼úÀÇ Áøº¸
- ¸¹Àº Ư¼ºÀ» °¡Áø ÷°¡Á¦ÀÇ Áö¼ÓÀû ¿¬±¸°³¹ß(¹ÙÀÌ¿Àº£À̽º)
- ½ÃÀåÀÇ °úÁ¦
- ±ÔÁ¦ÀÇ ¾ö°ÝÈ¿Í Ã·°¡Á¦ÀÇ ÀûÇÕ¼º¿¡ °üÇÑ ¹®Á¦ Áõ°¡
Porter's Five Force : ÀǾàǰ ÷°¡Á¦ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸
Porter's Five Force Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ´ç½ÅÀº ´õ °ÀÎÇÑ ½ÃÀå¿¡¼ Æ÷Áö¼Å´×À» º¸ÀåÇÒ ¼ö ÀÖ½À´Ï´Ù.
PESTLE ºÐ¼® : ÀǾàǰ ÷°¡Á¦ ½ÃÀå¿¡¼ ¿ÜºÎ·ÎºÎÅÍÀÇ ¿µÇâ ÆÄ¾Ç
¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÀǾàǰ ÷°¡Á¦ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ»ÇÕ´Ï´Ù. ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÏ¸é ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå Á¡À¯À² ºÐ¼® : ÀǾàǰ ÷°¡Á¦ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç
ÀǾàǰ ÷°¡Á¦ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õ´Â °æÀïÀÌ Ä¡¿ÇØÁö¸é¼ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» Çϱâ À§ÇØ ÇÊ¿äÇÑ Áö°ß ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.
FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º : ÀǾàǰ ÷°¡Á¦ ½ÃÀå¿¡¼ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡
FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÀǾàǰ ÷°¡Á¦ ½ÃÀå¿¡¼ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. 4°³ÀÇ »çºÐ¸éÀ» ÅëÇØ º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÎ¹®ÈÇϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.
Àü·« ºÐ¼® ¹× ±ÇÀå : ÀǾàǰ ÷°¡Á¦ ½ÃÀå¿¡¼ ¼º°øÀ» À§ÇÑ ±æÀ» ±×¸®±â
ÀǾàǰ ÷°¡Á¦ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼ÀÇ ÇÁ·¹Á𽺠°È¸¦ ¸ñÇ¥·Î ÇÏ´Â ±â¾÷¿¡ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖ´Â ½Ã½ºÅÛÀ» ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.
1. ½ÃÀå ħÅõ: ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.
2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϰí, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.
3. ½ÃÀå ´Ù¾çÈ: ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.
4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.
5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °Á¶ÇÕ´Ï´Ù.
¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.
1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?
2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?
3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?
4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?
5. º¥´õ ½ÃÀå ÁøÀÔ¡¤Ã¶¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?
¸ñÂ÷
Á¦1Àå ¼¹®
Á¦2Àå Á¶»ç ¹æ¹ý
Á¦3Àå ÁÖ¿ä ¿ä¾à
Á¦4Àå ½ÃÀå °³¿ä
Á¦5Àå ½ÃÀå ÀλçÀÌÆ®
- ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀÎ
- ¼¼°è¿¡¼ ¾ÏÀ̳ª ±âŸ ¸¸¼ºÁúȯ, °¨¿°ÁõÀÇ ¹ß»ý·üÀÌ »ó½Â
- ÀǾàǰ ¾÷°èÀÇ ¼ºÀå°ú Á¦³×¸¯ ÀǾàǰ ¹× Èñ±ÍÀǾàǰÀÇ Å« ¼ö¿ä
- ´Ù±â´É ÷°¡Á¦ÀÇ Á¦Á¶¿¡ ÁßÁ¡À» µÐ´Ù
- ¾ïÁ¦¿äÀÎ
- °íµµÀÇ Ã·°¡Á¦ÀÇ Á¦Á¶¿¡ ¼ö¹ÝÇÏ´Â °íºñ¿ë
- ±âȸ
- ÷°¡Á¦ÀÇ ³ª³ë±â¼ú¿¡ ÀÖ¾î¼ÀÇ ±â¼úÀû Áøº¸
- ´Ù¾çÇÑ Æ¯¼ºÀ» °®´Â ÷°¡Á¦ÀÇ Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß(¹ÙÀÌ¿Àº£À̽º)
- °úÁ¦
- ±ÔÁ¦ÀÇ ¾ö°ÝÈ¿Í Ã·°¡Á¦ÀÇ ÀûÇÕ¼º¿¡ °üÇÑ ¹®Á¦ Áõ°¡
- ½ÃÀå ¼¼ºÐÈ ºÐ¼®
- À¯Çü : À¯±â ÷°¡Á¦ÀÇ ÀáÀçÀû ¼ö¿ä¿Í »ç¿ë
- Á¦Á¦ : ¾à¹°Àü´ÞÀÇ Æí¸®¼ºÀ¸·ÎºÎÅÍ °æ±¸ Á¦Á¦ ¼ö¿ä°¡ ³ôÀº
- ±â´É: ÄÚÆÃÁ¦´Â ¾àÁ¦¸¦ ¹°¸®Àû, ÈÇÐÀûÀ¸·Î º¸È£ÇÕ´Ï´Ù
- Porter's Five Forces ºÐ¼®
- PESTEL ºÐ¼®
- Á¤Ä¡Àû
- °æÁ¦
- »ç±³
- ±â¼úÀû
- ¹ý·ü»ó
- ȯ°æ
Á¦6Àå ÀǾàǰ ÷°¡Á¦ ½ÃÀå : À¯Çüº°
- ¹«±â
- ź»êÄ®½·
- ÀλêÄ®½·
- Ȳ»êÄ®½·
- ¾Ï¿°
- ±Ý¼Ó »êȹ°
- À¯±â³ó
- ź¼öȹ°
- À¯Áö ÈÇÐÁ¦Ç°
- Áö¹æ ¾ËÄÚ¿Ã
- ±Û¸®¼¼¸°
- ¹Ì³×¶ö ½ºÆ¼¾î·¹ÀÌÆ®
- ¼®À¯ÈÇÐÁ¦Ç°
- ¾ÆÅ©¸± Æú¸®¸Ó
- ±Û¸®ÄÝ
- ºÎÆ¿·»±Û¸®ÄÝ
- µð¿¡Æ¿·»±Û¸®ÄÝ
- ¿¡Æ¿·»±Û¸®ÄÝ
- Çí½Ç·»±Û¸®ÄÝ
- ¸¶Å©·Î°ñ
- ¸¶ÀÌÅ©·Î±Û¸®ÄÝ
- ÇÁ·ÎÆÄÀÏ·»±Û¸®ÄÝ
- ±¤¹° źȼö¼Ò
- Æ÷ºñµ·
- ´Ü¹éÁú
Á¦7Àå ÀǾàǰ ÷°¡Á¦ ½ÃÀå : ó¹æº°
- °æ±¸ Á¦Çü
- Çϵå Á©¶óƾ ĸ½¶
- ¾×ü Á¦Çü
- ¼ÒÇÁÆ®Á©¶óƾ ĸ½¶
- ÅÂºí¸´
- ºñ°æ±¸ Á¦Çü
- ±¹¼Ò¿ë Á¦Á¦
Á¦8Àå ÀǾàǰ ÷°¡Á¦ ½ÃÀå : ±â´Éº°
- ¹ÙÀδõ
- ÄÚÆÃÁ¦
- Âø»öÁ¦
- ºØ±«Á¦
- À¯ÈÁ¦
- ÃæÀüÁ¦¿Í Èñ¼®Á¦
- Çâ·á ¹× °¨¹Ì·á
- À±È°Á¦¿Í À±È°Á¦
- ¹æºÎÁ¦
- ÇöŹÁ¦ ¹× Á¡¼ºÁ¦
Á¦9Àå ÀǾàǰ ÷°¡Á¦ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°
- ¹ÙÀÌ¿ÀÀǾàǰ±â¾÷
- °è¾à Á¦Á¶ Á¶Á÷
- Á¦¾àȸ»ç
- ¿¬±¸½Ç
Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ÀǾàǰ ÷°¡Á¦ ½ÃÀå
- ¾Æ¸£ÇîÆ¼³ª
- ºê¶óÁú
- ij³ª´Ù
- ¸ß½ÃÄÚ
- ¹Ì±¹
Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÀǾàǰ ÷°¡Á¦ ½ÃÀå
- È£ÁÖ
- Áß±¹
- Àεµ
- Àεµ³×½Ã¾Æ
- ÀϺ»
- ¸»·¹À̽þÆ
- Çʸ®ÇÉ
- ½Ì°¡Æ÷¸£
- Çѱ¹
- ´ë¸¸
- ű¹
- º£Æ®³²
Á¦12Àå À¯·´¡¤Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀǾàǰ ÷°¡Á¦ ½ÃÀå
- µ§¸¶Å©
- ÀÌÁýÆ®
- Çɶõµå
- ÇÁ¶û½º
- µ¶ÀÏ
- À̽º¶ó¿¤
- ÀÌÅ»¸®¾Æ
- ³×´ú¶õµå
- ³ªÀÌÁö¸®¾Æ
- ³ë¸£¿þÀÌ
- Æú¶õµå
- īŸ¸£
- ·¯½Ã¾Æ
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ³²¾ÆÇÁ¸®Ä«
- ½ºÆäÀÎ
- ½º¿þµ§
- ½ºÀ§½º
- ÅÍŰ
- ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
- ¿µ±¹
Á¦13Àå °æÀï ±¸µµ
- ½ÃÀå Á¡À¯À² ºÐ¼® 2023
- FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
- °æÀï ½Ã³ª¸®¿À ºÐ¼®
- EvonikÀÇ »õ·Î¿î ½ºÇÁ·¹ÀÌ °ÇÁ¶ ½Ã¼³Àº °æ±¸ ÷°¡Á¦ÀÇ ¼¼°è °ø±Þ°ú Áö¼Ó°¡´É¼ºÀ» °ÈÇÕ´Ï´Ù
- Roquette°¡ IFF Pharma Solutions¸¦ Àü·«ÀûÀ¸·Î ÀμöÇØ, ¾à¹°Àü´Þ ¼Ö·ç¼Ç ¹× ÷°¡Á¦ ½ÃÀå¿¡ ÀÖ¾î¼ÀÇ ¼¼°èÀÇ ¿µÇâ·ÂÀ» °È
- Asahi Kaseiȼº, Àú¾ÆÁú»ê¿°ÀÇ Ceolus MCC ÷°¡Á¦¿Í »ý»ê È®´ë·Î ÀǾàǰÀÇ ¾ÈÀü¼ºÀ» Çâ»ó
- Roquette°¡ ½À±â ´ëÃ¥ÀÇ ½Å±â¼úÀ» ¹ßÇ¥
- Clariant, ¹Ù¸£¼¿·Î³ªÀÇ CPHI·Î APIÀÇ ¾ÈÁ¤¼º°ú ¿ëÇØ¼ºÀ» Çâ»ó½ÃŰ´Â »õ·Î¿î ÷°¡Á¦ ½Ã¸®Á ¹ßÇ¥
- BASF¿Í IFF°¡ °¡»ó Á¦¾à ¾î½Ã½ºÅÏÆ® Ç÷§Æû ZoomLab¿¡¼ Á¦ÈÞ
- Lubrizol, ¼ö»ó °æ·ÂÀÌ ÀÖ´Â Apisolex ÷°¡Á¦¸¦ Welton Pharma¿¡ ¶óÀ̼±½º °ø¿©ÇØ, »õ·Î¿î ¾Ï Ä¡·áÁ¦À» °³¹ß
- Ingredion, °íºÎ°¡°¡Ä¡ ÀǾàǰ ¿ø·á¿¡ ´ëÇÑ Àü·«Àû ÅõÀÚ È®´ë¸¦ ¹ßÇ¥
- DFE Pharma, Lactohale 400ÀÇ ¹ß¸Å¿¡ ÀÇÇØ ÈíÀÔ Æ÷Æ®Æú¸®¿À¸¦ È®´ë
- EvonicÀº ¹Ì±¹ Á¤ºÎ¿Í Á¦ÈÞÇÏ¿© ¹Ì±¹¿¡ mRNA ±â¹Ý Ä¡·áÁ¦¸¦ À§ÇÑ »õ·Î¿î ÁöÁú »ý»ê ½Ã¼³À» °Ç¼³Çϱâ À§ÇØ 2¾ï 2,000¸¸ ´Þ·¯¸¦ ÅõÀÚÇÕ´Ï´Ù.
- LubrizolÀÌ Apisolex ±â¼úÀ» ¹ßÇ¥
- Univar Solutions, Ashland¿ÍÀÇ »õ·Î¿î ÆÇ¸Å°è¾àÀ» ÅëÇØ ÀǾàǰ Æ÷Æ®Æú¸®¿À È®´ë
- Azelis, Roquette°úÀÇ Á¦ÈÞ È®´ë·Î Àεµ¿¡¼ÀÇ ÀǾàǰ »ç¾÷À» °È
- Roquette, Crest CelluloseÀÇ ¿ÏÀü Àμö¿¡ ÀÇÇØ ½Ä¹° À¯·¡ ÷°¡Á¦ Æ÷Æ®Æú¸®¿ÀÀÇ ¼¼°è Àü°³¸¦ È®´ë
- Àü·« ºÐ¼®°ú Á¦¾È
±â¾÷ ¸ñ·Ï
- ABITEC Corporation
- Actylis
- Archer Daniels Midland Company
- ARMOR PROTEINES SAS
- Asahi Kasei Corporation
- Ashland Inc.
- BASF SE
- BIOGRUND GmbH
- Chemische Fabrik Budenheim KG
- Clariant AG
- Colorcon Inc.
- Corel Pharma Chem Private Limited
- Croda International Plc
- Darling Ingredients, Inc.
- DFE Pharma GmbH & Co KG
- DuPont de Nemours, Inc.
- Evonik Industries AG
- Fuji Chemical Industries Co., Ltd.
- GATTEFOSSE SAS
- Innophos Holdings, Inc.
- International Flavors & Fragrances Inc.
- JRS PHARMA GmbH Co. KG
- Kerry Group PLC
- Lipoid GmbH
- Lubrizol Corporation
- L'AIR LIQUIDE SA
- Mallinckrodt plc
- MEGGLE GmbH & Co. KG
- Merck KGaA
- Nagase & Co., Ltd.
- Nipon Soda Co., Ltd.
- NOF Corporation
- Omya International AG
- Peter Greven GmbH & Co. KG
- RT Vanderbilt Holding Company, Inc.
- Roquette Freres SA
- Shin-Etsu Chemical Co., Ltd.
- Solvay SA
- SPI Pharma, Inc.
- Thermo Fisher Scientific Inc.
JHS
The Pharmaceutical Excipient Market was valued at USD 8.62 billion in 2023, expected to reach USD 9.22 billion in 2024, and is projected to grow at a CAGR of 7.62%, to USD 14.42 billion by 2030.
Pharmaceutical excipients are inactive substances formulated alongside the active pharmaceutical ingredient (API) of a medication, serving critical roles in promoting stability, bioavailability, and delivery of the drug. They are essential in various drug formulations, offering functionalities such as binding, coating, solubilizing, and preserving. Excipients are utilized across several applications, including oral, topical, parenteral, and inhalation preparations, with key end-use sectors comprising hospitals, clinics, and research institutions. The growth of the pharmaceutical excipient market is primarily driven by the expanding pharmaceutical sector, increased drug approvals, and significant advancements in drug delivery systems. Additionally, the rise in demand for oral medications and technologically advanced multifunctional excipients is opening avenues for market expansion. However, the market faces challenges, such as stringent regulatory guidelines and high costs associated with the development of new excipients, which can hinder growth. Limitations include potential risks of excipient-drug interactions and variability in excipient characteristics, impacting formulation consistency.
KEY MARKET STATISTICS |
Base Year [2023] |
USD 8.62 billion |
Estimated Year [2024] |
USD 9.22 billion |
Forecast Year [2030] |
USD 14.42 billion |
CAGR (%) |
7.62% |
Among the latest opportunities are the rising focus on biopharmaceuticals and the growing implementation of personalized medicine, which necessitates novel excipient development to cater to unique delivery and stability needs. There's a continuous push towards natural and sustainable excipients due to growing environmental awareness, providing an excellent area for innovation. Exploring collaborations with biotech firms for excipient development in peptide and protein formulations can further drive growth. Research into co-processed and multifunctional excipients can also yield competitive advantages. The market is highly dynamic, characterized by rapid technological advancements and a robust pipeline of next-generation excipients. Businesses should strategically focus on R&D investments in innovative excipient types and formulations, leveraging collaborations to enhance capabilities and meet the diverse demands of modern drug formulations. Identifying niche markets with unmet excipient needs and tailoring solutions accordingly can secure a significant market position.
Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmaceutical Excipient Market
The Pharmaceutical Excipient Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.
- Market Drivers
- Rising incidence of cancer and other chronic and infectious diseases worldwide
- Growth of the pharmaceuticals industry coupled with significant demand for generics & orphan drugs
- Significant emphasis on the production of multifunctional excipients
- Market Restraints
- High cost associated with the production of advanced excipient
- Market Opportunities
- Technological advancements in nanotechnology for excipients
- Ongoing research and development of excipients with numerous properties (Biobased)
- Market Challenges
- Increasing regulatory stringency and issues regarding the compatibility of excipients
Porter's Five Forces: A Strategic Tool for Navigating the Pharmaceutical Excipient Market
Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmaceutical Excipient Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.
PESTLE Analysis: Navigating External Influences in the Pharmaceutical Excipient Market
External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmaceutical Excipient Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.
Market Share Analysis: Understanding the Competitive Landscape in the Pharmaceutical Excipient Market
A detailed market share analysis in the Pharmaceutical Excipient Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.
FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmaceutical Excipient Market
The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmaceutical Excipient Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.
Strategy Analysis & Recommendation: Charting a Path to Success in the Pharmaceutical Excipient Market
A strategic analysis of the Pharmaceutical Excipient Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.
Key Company Profiles
The report delves into recent significant developments in the Pharmaceutical Excipient Market, highlighting leading vendors and their innovative profiles. These include ABITEC Corporation, Actylis, Archer Daniels Midland Company, ARMOR PROTEINES S.A.S., Asahi Kasei Corporation, Ashland Inc., BASF SE, BIOGRUND GmbH, Chemische Fabrik Budenheim KG, Clariant AG, Colorcon Inc., Corel Pharma Chem Private Limited, Croda International Plc, Darling Ingredients, Inc., DFE Pharma GmbH & Co KG, DuPont de Nemours, Inc., Evonik Industries AG, Fuji Chemical Industries Co., Ltd., GATTEFOSSE SAS, Innophos Holdings, Inc., International Flavors & Fragrances Inc., JRS PHARMA GmbH + Co. KG, Kerry Group P.L.C., Lipoid GmbH, Lubrizol Corporation, L'AIR LIQUIDE S.A., Mallinckrodt plc, MEGGLE GmbH & Co. KG, Merck KGaA, Nagase & Co., Ltd., Nipon Soda Co., Ltd., NOF Corporation, Omya International AG, Peter Greven GmbH & Co. KG, R.T. Vanderbilt Holding Company, Inc., Roquette Freres S.A., Shin-Etsu Chemical Co., Ltd., Solvay S.A., SPI Pharma, Inc., and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
This research report categorizes the Pharmaceutical Excipient Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Based on Type, market is studied across Inorganic and Organic. The Inorganic is further studied across Calcium Carbonate, Calcium Phosphate, Calcium Sulfate, Halites, and Metal Oxides. The Organic is further studied across Carbohydrates, Oleochemicals, Petrochemicals, and Proteins. The Carbohydrates is further studied across Cellulose, Starch, and Sugars. The Oleochemicals is further studied across Fatty Alcohols, Glycerin, and Mineral Stearates. The Petrochemicals is further studied across Acrylic Polymers, Glycols, Mineral Hydrocarbons, and Povidones. The Glycols is further studied across Butylene Glycol, Diethylene Glycol, Ethylene Glycol, Hexylene Glycol, Macrogol, Microglycol, and Propylene Glycol.
- Based on Formulation, market is studied across Oral Formulations, Parenteral Formulations, and Topical Formulations. The Oral Formulations is further studied across Hard Gelatin Capsules, Liquid Formulations, Soft Gelatin Capsules, and Tablets.
- Based on Function, market is studied across Binders, Coating Agents, Colorants, Disintegrants, Emulsifying Agents, Fillers & Diluents, Flavoring Agents & Sweeteners, Lubricants & Glidants, Preservatives, and Suspending & Viscosity Agents.
- Based on End-User, market is studied across Biopharmaceutical Companies, Contract Manufacturing Organizations, Pharmaceutical Companies, and Research Laboratories.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
The report offers a comprehensive analysis of the market, covering key focus areas:
1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.
2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.
3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.
4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.
5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.
The report also answers critical questions to aid stakeholders in making informed decisions:
1. What is the current market size, and what is the forecasted growth?
2. Which products, segments, and regions offer the best investment opportunities?
3. What are the key technology trends and regulatory influences shaping the market?
4. How do leading vendors rank in terms of market share and competitive positioning?
5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Rising incidence of cancer and other chronic and infectious diseases worldwide
- 5.1.1.2. Growth of the pharmaceuticals industry coupled with significant demand for generics & orphan drugs
- 5.1.1.3. Significant emphasis on the production of multifunctional excipients
- 5.1.2. Restraints
- 5.1.2.1. High cost associated with the production of advanced excipient
- 5.1.3. Opportunities
- 5.1.3.1. Technological advancements in nanotechnology for excipients
- 5.1.3.2. Ongoing research and development of excipients with numerous properties (Biobased)
- 5.1.4. Challenges
- 5.1.4.1. Increasing regulatory stringency and issues regarding the compatibility of excipients
- 5.2. Market Segmentation Analysis
- 5.2.1. Type: Potential demand and utilization of organic excipients
- 5.2.2. Formulation: Significant demand for oral formulations owing to its convenient drug delivery
- 5.2.3. Function: Coating agents provide physical and chemical protection for the drug
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
- 5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
6. Pharmaceutical Excipient Market, by Type
- 6.1. Introduction
- 6.2. Inorganic
- 6.2.1. Calcium Carbonate
- 6.2.2. Calcium Phosphate
- 6.2.3. Calcium Sulfate
- 6.2.4. Halites
- 6.2.5. Metal Oxides
- 6.3. Organic
- 6.3.1. Carbohydrates
- 6.3.1.1. Cellulose
- 6.3.1.2. Starch
- 6.3.1.3. Sugars
- 6.3.2. Oleochemicals
- 6.3.2.1. Fatty Alcohols
- 6.3.2.2. Glycerin
- 6.3.2.3. Mineral Stearates
- 6.3.3. Petrochemicals
- 6.3.3.1. Acrylic Polymers
- 6.3.3.2. Glycols
- 6.3.3.2.1. Butylene Glycol
- 6.3.3.2.2. Diethylene Glycol
- 6.3.3.2.3. Ethylene Glycol
- 6.3.3.2.4. Hexylene Glycol
- 6.3.3.2.5. Macrogol
- 6.3.3.2.6. Microglycol
- 6.3.3.2.7. Propylene Glycol
- 6.3.3.3. Mineral Hydrocarbons
- 6.3.3.4. Povidones
- 6.3.4. Proteins
7. Pharmaceutical Excipient Market, by Formulation
- 7.1. Introduction
- 7.2. Oral Formulations
- 7.2.1. Hard Gelatin Capsules
- 7.2.2. Liquid Formulations
- 7.2.3. Soft Gelatin Capsules
- 7.2.4. Tablets
- 7.3. Parenteral Formulations
- 7.4. Topical Formulations
8. Pharmaceutical Excipient Market, by Function
- 8.1. Introduction
- 8.2. Binders
- 8.3. Coating Agents
- 8.4. Colorants
- 8.5. Disintegrants
- 8.6. Emulsifying Agents
- 8.7. Fillers & Diluents
- 8.8. Flavoring Agents & Sweeteners
- 8.9. Lubricants & Glidants
- 8.10. Preservatives
- 8.11. Suspending & Viscosity Agents
9. Pharmaceutical Excipient Market, by End-User
- 9.1. Introduction
- 9.2. Biopharmaceutical Companies
- 9.3. Contract Manufacturing Organizations
- 9.4. Pharmaceutical Companies
- 9.5. Research Laboratories
10. Americas Pharmaceutical Excipient Market
- 10.1. Introduction
- 10.2. Argentina
- 10.3. Brazil
- 10.4. Canada
- 10.5. Mexico
- 10.6. United States
11. Asia-Pacific Pharmaceutical Excipient Market
- 11.1. Introduction
- 11.2. Australia
- 11.3. China
- 11.4. India
- 11.5. Indonesia
- 11.6. Japan
- 11.7. Malaysia
- 11.8. Philippines
- 11.9. Singapore
- 11.10. South Korea
- 11.11. Taiwan
- 11.12. Thailand
- 11.13. Vietnam
12. Europe, Middle East & Africa Pharmaceutical Excipient Market
- 12.1. Introduction
- 12.2. Denmark
- 12.3. Egypt
- 12.4. Finland
- 12.5. France
- 12.6. Germany
- 12.7. Israel
- 12.8. Italy
- 12.9. Netherlands
- 12.10. Nigeria
- 12.11. Norway
- 12.12. Poland
- 12.13. Qatar
- 12.14. Russia
- 12.15. Saudi Arabia
- 12.16. South Africa
- 12.17. Spain
- 12.18. Sweden
- 12.19. Switzerland
- 12.20. Turkey
- 12.21. United Arab Emirates
- 12.22. United Kingdom
13. Competitive Landscape
- 13.1. Market Share Analysis, 2023
- 13.2. FPNV Positioning Matrix, 2023
- 13.3. Competitive Scenario Analysis
- 13.3.1. Evonik's new spray drying facility enhances global supply and sustainability of oral excipients
- 13.3.2. Roquette's strategic acquisition of IFF Pharma Solutions to bolster global influence in drug delivery solutions and excipients market
- 13.3.3. Asahi Kasei enhances pharmaceutical safety with low-nitrite Ceolus MCC excipient and expanded production
- 13.3.4. Roquette Introduces New Advancement in Moisture Protection
- 13.3.5. Clariant Launches New Range Of Excipients To Improve Stability And Solubility of Apis at CPHI Barcelona
- 13.3.6. BASF, IFF Partner on Virtual Pharma Assistant Platform ZoomLab
- 13.3.7. Lubrizol Licenses Award-Winning Apisolex Excipient to Welton Pharma to Develop a Novel Cancer Therapeutic
- 13.3.8. Ingredion Announces Strategic Investments Expanding Into High-Value Pharmaceutical Ingredients
- 13.3.9. DFE Pharma Expands its Inhalation Portfolio with the Launch of Lactohale 400
- 13.3.10. Evonik invests USD 220 million in partnership with the U.S. Government to build a new lipid production facility for mRNA-based therapies in the U.S.
- 13.3.11. Lubrizol Launches Apisolex Technology
- 13.3.12. Univar Solutions Expands Pharmaceutical Products Portfolio Through New Distribution Agreement with Ashland
- 13.3.13. Azelis Strengthens Its Pharmaceutical Presence in India By Expanding its Partnership With Roquette
- 13.3.14. Roquette Expands Global Reach of Plant-Based Excipients Portfolio with Complete Acquisition of Crest Cellulose
- 13.4. Strategy Analysis & Recommendation
Companies Mentioned
- 1. ABITEC Corporation
- 2. Actylis
- 3. Archer Daniels Midland Company
- 4. ARMOR PROTEINES S.A.S.
- 5. Asahi Kasei Corporation
- 6. Ashland Inc.
- 7. BASF SE
- 8. BIOGRUND GmbH
- 9. Chemische Fabrik Budenheim KG
- 10. Clariant AG
- 11. Colorcon Inc.
- 12. Corel Pharma Chem Private Limited
- 13. Croda International Plc
- 14. Darling Ingredients, Inc.
- 15. DFE Pharma GmbH & Co KG
- 16. DuPont de Nemours, Inc.
- 17. Evonik Industries AG
- 18. Fuji Chemical Industries Co., Ltd.
- 19. GATTEFOSSE SAS
- 20. Innophos Holdings, Inc.
- 21. International Flavors & Fragrances Inc.
- 22. JRS PHARMA GmbH + Co. KG
- 23. Kerry Group P.L.C.
- 24. Lipoid GmbH
- 25. Lubrizol Corporation
- 26. L'AIR LIQUIDE S.A.
- 27. Mallinckrodt plc
- 28. MEGGLE GmbH & Co. KG
- 29. Merck KGaA
- 30. Nagase & Co., Ltd.
- 31. Nipon Soda Co., Ltd.
- 32. NOF Corporation
- 33. Omya International AG
- 34. Peter Greven GmbH & Co. KG
- 35. R.T. Vanderbilt Holding Company, Inc.
- 36. Roquette Freres S.A.
- 37. Shin-Etsu Chemical Co., Ltd.
- 38. Solvay S.A.
- 39. SPI Pharma, Inc.
- 40. Thermo Fisher Scientific Inc.